Long-term efficacy and safety of lamotrigine for all types of bipolar disorder

Yoshinori Watanabe,1,2 Seiji Hongo2 1Himorogi Psychiatric Institute, Tokyo, 2Nanko Clinic of Psychiatry, Shirakawa city, Fukushima, Japan Background: We investigated whether the long-term efficacy and safety of lamotrigine (LTG) for bipolar disorder (BP) differs between disease types (BP-I, BP-II,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Watanabe Y, Hongo S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	lamotrigine bipolar disorder long-term efficacy antidepressant skin rash anxiety Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/42823fff5f74466fa131bfdc537654dc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:42823fff5f74466fa131bfdc537654dc
record_format	dspace
spelling	oai:doaj.org-article:42823fff5f74466fa131bfdc537654dc2021-12-02T02:32:17ZLong-term efficacy and safety of lamotrigine for all types of bipolar disorder1178-2021https://doaj.org/article/42823fff5f74466fa131bfdc537654dc2017-03-01T00:00:00Zhttps://www.dovepress.com/long-term-efficacy-and-safety-of-lamotrigine-for-all-types-of-bipolar--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Yoshinori Watanabe,1,2 Seiji Hongo2 1Himorogi Psychiatric Institute, Tokyo, 2Nanko Clinic of Psychiatry, Shirakawa city, Fukushima, Japan Background: We investigated whether the long-term efficacy and safety of lamotrigine (LTG) for bipolar disorder (BP) differs between disease types (BP-I, BP-II, or BP not otherwise specified [BP-NOS]), and the efficacy of the concomitant use of antidepressants (ADs).Methods: For >1 year, we observed 445 outpatients with BP (diagnosed by DSM-IV criteria) who initiated LTG treatment between July 1 and October 31, 2011, using the Himorogi Self-rating Depression (HSDS) and Anxiety Scales and the Clinical Global Impression-Improvement scale and also recorded adverse events.Results: Treatment efficacy was observed at week 4, with the improved HSDS scores sustained until week 52 for all types of BP; 50% of the patients with any type of BP could be treated with LTG for 1 year, whereas ~40% could be treated for >1.5 years. However, 25% of the patients were withdrawn within the first 4 weeks. The overall incidence of adverse events was 22.9% (104/455): 34.1% (14/41) for BP-I, 22.7% (15/66) for BP-II, and 22.2% (75/338) for BP-NOS. The most common adverse event was skin rash: 22.0% for BP-I, 16.7% for BP-II, and 12.1% for BP-NOS.Limitations: There was no control group. Data were collected retrospectively.Conclusion: With careful and adequate titration, long-term treatment with LTG is possible for any type of BP, with BP-NOS patients, the largest population in clinical practice, responding particularly well. Symptoms can improve with or without ADs. Large-scale prospective studies of the efficacy of ADs in bipolar treatment are warranted. Keywords: lamotrigine, bipolar disorder, long-term efficacy, antidepressant, skin rash, anxietyWatanabe YHongo SDove Medical Pressarticlelamotriginebipolar disorderlong-term efficacyantidepressantskin rashanxietyNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 843-854 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	lamotrigine bipolar disorder long-term efficacy antidepressant skin rash anxiety Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	lamotrigine bipolar disorder long-term efficacy antidepressant skin rash anxiety Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Watanabe Y Hongo S Long-term efficacy and safety of lamotrigine for all types of bipolar disorder
description	Yoshinori Watanabe,1,2 Seiji Hongo2 1Himorogi Psychiatric Institute, Tokyo, 2Nanko Clinic of Psychiatry, Shirakawa city, Fukushima, Japan Background: We investigated whether the long-term efficacy and safety of lamotrigine (LTG) for bipolar disorder (BP) differs between disease types (BP-I, BP-II, or BP not otherwise specified [BP-NOS]), and the efficacy of the concomitant use of antidepressants (ADs).Methods: For >1 year, we observed 445 outpatients with BP (diagnosed by DSM-IV criteria) who initiated LTG treatment between July 1 and October 31, 2011, using the Himorogi Self-rating Depression (HSDS) and Anxiety Scales and the Clinical Global Impression-Improvement scale and also recorded adverse events.Results: Treatment efficacy was observed at week 4, with the improved HSDS scores sustained until week 52 for all types of BP; 50% of the patients with any type of BP could be treated with LTG for 1 year, whereas ~40% could be treated for >1.5 years. However, 25% of the patients were withdrawn within the first 4 weeks. The overall incidence of adverse events was 22.9% (104/455): 34.1% (14/41) for BP-I, 22.7% (15/66) for BP-II, and 22.2% (75/338) for BP-NOS. The most common adverse event was skin rash: 22.0% for BP-I, 16.7% for BP-II, and 12.1% for BP-NOS.Limitations: There was no control group. Data were collected retrospectively.Conclusion: With careful and adequate titration, long-term treatment with LTG is possible for any type of BP, with BP-NOS patients, the largest population in clinical practice, responding particularly well. Symptoms can improve with or without ADs. Large-scale prospective studies of the efficacy of ADs in bipolar treatment are warranted. Keywords: lamotrigine, bipolar disorder, long-term efficacy, antidepressant, skin rash, anxiety
format	article
author	Watanabe Y Hongo S
author_facet	Watanabe Y Hongo S
author_sort	Watanabe Y
title	Long-term efficacy and safety of lamotrigine for all types of bipolar disorder
title_short	Long-term efficacy and safety of lamotrigine for all types of bipolar disorder
title_full	Long-term efficacy and safety of lamotrigine for all types of bipolar disorder
title_fullStr	Long-term efficacy and safety of lamotrigine for all types of bipolar disorder
title_full_unstemmed	Long-term efficacy and safety of lamotrigine for all types of bipolar disorder
title_sort	long-term efficacy and safety of lamotrigine for all types of bipolar disorder
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/42823fff5f74466fa131bfdc537654dc
work_keys_str_mv	AT watanabey longtermefficacyandsafetyoflamotrigineforalltypesofbipolardisorder AT hongos longtermefficacyandsafetyoflamotrigineforalltypesofbipolardisorder
_version_	1718402403833741312

Long-term efficacy and safety of lamotrigine for all types of bipolar disorder

Ejemplares similares